344 related articles for article (PubMed ID: 17377788)
21. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Fantin VR; Richon VM
Clin Cancer Res; 2007 Dec; 13(24):7237-42. PubMed ID: 18094401
[TBL] [Abstract][Full Text] [Related]
22. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Jones P; Altamura S; De Francesco R; Paz OG; Kinzel O; Mesiti G; Monteagudo E; Pescatore G; Rowley M; Verdirame M; Steinkühler C
J Med Chem; 2008 Apr; 51(8):2350-3. PubMed ID: 18370373
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
24. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Frew AJ; Johnstone RW; Bolden JE
Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel small-molecule histone deacetylase inhibitors by medium-throughput screening using a fluorigenic assay.
Wegener D; Hildmann C; Riester D; Schober A; Meyer-Almes FJ; Deubzer HE; Oehme I; Witt O; Lang S; Jaensch M; Makarov V; Lange C; Busse B; Schwienhorst A
Biochem J; 2008 Jul; 413(1):143-50. PubMed ID: 18384290
[TBL] [Abstract][Full Text] [Related]
26. Histone deacetylase inhibitors: from bench to clinic.
Paris M; Porcelloni M; Binaschi M; Fattori D
J Med Chem; 2008 Mar; 51(6):1505-29. PubMed ID: 18247554
[No Abstract] [Full Text] [Related]
27. [Development of HDAC inhibitors].
Sowa Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1665-8. PubMed ID: 20841929
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
29. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Acharya MR; Sparreboom A; Venitz J; Figg WD
Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
[TBL] [Abstract][Full Text] [Related]
30. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors in myelodysplastic syndrome.
Bhalla K; List A
Best Pract Res Clin Haematol; 2004 Dec; 17(4):595-611. PubMed ID: 15494297
[TBL] [Abstract][Full Text] [Related]
32. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Belvedere S; Witter DJ; Yan J; Secrist JP; Richon V; Miller TA
Bioorg Med Chem Lett; 2007 Jul; 17(14):3969-71. PubMed ID: 17507219
[TBL] [Abstract][Full Text] [Related]
33. Rational combinations using HDAC inhibitors.
Bots M; Johnstone RW
Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
[TBL] [Abstract][Full Text] [Related]
34. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation.
Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM
Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Blanchard F; Chipoy C
Drug Discov Today; 2005 Feb; 10(3):197-204. PubMed ID: 15708534
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
Glauben R; Siegmund B
Methods Mol Biol; 2009; 512():365-76. PubMed ID: 19347289
[TBL] [Abstract][Full Text] [Related]
37. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
Prince HM; Bishton MJ; Johnstone RW
Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200
[TBL] [Abstract][Full Text] [Related]
38. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
39. Alpha-mercaptoketone based histone deacetylase inhibitors.
Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]